Opaleye Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Opaleye Management’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-156,500	Closed	-$1.66M	–	60
2021 Q1	$1.66M	Buy	+156,500	New	+$1.95M	0.24%	51
2016 Q2	–	Sell	-25,000	Closed	-$417K	–	58
2016 Q1	$417K	Buy	+25,000	New	+$501K	0.26%	49
2015 Q4	–	Sell	-43,800	Closed	-$2.27M	–	55
2015 Q3	$2.27M	Buy	+43,800	New	+$2.88M	1.12%	35

Other funds holding ALPN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Opaleye Management's ALPN Position: Q2 2021 in Review

Opaleye Management sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2021, closing a stake of 156,500 shares — an estimated $1.66M sold.

Opaleye Management first reported a position in ALPN in Q3 2015 and held it in 3 quarters. The position peaked at $2.27M in Q3 2015. 47 funds tracked by Wall St. Rank hold ALPN as of Q2 2021.

Opaleye Management reported no remaining Alpine Immune Sciences Inc position as of Q2 2021 after selling out during the quarter.
Opaleye Management sold 156,500 Alpine Immune Sciences Inc shares in Q2 2021, an estimated $1.66M.
Opaleye Management first reported a position in Alpine Immune Sciences Inc in Q3 2015 and held it in 3 quarters.
Opaleye Management's Alpine Immune Sciences Inc position peaked at $2.27M in Q3 2015.
47 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2021.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.